27 May Page 1 of PRODUCT MONOGRAPH. BRILINTA® ticagrelor tablets. 60 and 90 mg. Platelet Aggregation Inhibitor. AstraZeneca Canada Inc. 27 May This leaflet is part III of a three-part “Product. Monograph” published when BRILINTA® was approved for sale in Canada and is designed. Official health care professional site for BRILINTA® (ticagrelor) tablets, indicated to reduce the rate of CV death, MI, BRILINTA® (ticagrelor) [package insert].
|Published (Last):||5 June 2010|
|PDF File Size:||5.69 Mb|
|ePub File Size:||9.44 Mb|
|Price:||Free* [*Free Regsitration Required]|
Consider the risks and benefits of treatment, noting the probable increase in exposure to ticagrelor. You may brilinta package insert side effects related to AstraZeneca products by clicking here.
Only the mg dose strength is approved for use in patients with a history of MI 1 year after an ACS event. For at least the first brilinta package insert months following ACS, it is superior to clopidogrel.
BRILINTA has been shown to reduce the rate of inseert combined endpoint of cardiovascular death, myocardial infarction or stroke compared to clopidogrel. Brilinta package insert were excluded if they had a previous intracranial hemorrhage, gastrointestinal bleeding within 6 months, had a known bleeding diathesis or coagulation disorder, or required treatment with anticoagulants.
Share With a Friend
Apckage see package insert for additional information and possible brilinta package insert innsert ensure safe and effective use of this medication. Rule brilinta package insert other causes. Call your inset if you have new or unexpected shortness of breath or any side effect that bothers you or that does not go away. The difference in treatments was driven by CV death and MI with no difference in stroke.
After one year administer 60 mg twice daily. Patients with prior MI treated up to 48 months 1,3. Long-term use of ticagrelor in patients with prior myocardial infarction. Consider use of a parenteral anti-platelet in ACS patients requiring co-administration.
N Engl J Brilinta package insert. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. Instances of serious bleeding, such as internal bleeding, may require blood transfusions or surgery.
BRILINTA® (ticagrelor) tablets | For Health Care Professionals
Your doctor can decide what treatment is brilinta package insert. The difference between treatments was driven by CV death and MI with no difference in stroke. Food and Drug Administration. After any initial dose, use with aspirin mg per day.
These can be fatal. Strong inhibitors substantially increase ticagrelor exposure and so increase the risk of adverse events.
Ticagrelor and brilinta package insert active metabolite are approximately equipotent. Tell your doctor if you take brilinta package insert medicines that contain aspirin. BRILINTA is used with aspirin to lower your chance of having another serious problem pacakge your heart or blood vessels such as heart attack, stroke, or blood clots in your stent if you received one. Avoid maintenance doses of aspirin above mg daily.
Log In Search Go. Bleeding will also take longer than usual to stop. Medical Calculators – A thru Z.
FDA Internet Application Site (Accessdata) Error
The authors make no claims of the accuracy brilinta package insert the information contained herein; and these suggested doses are not a substitute for clinical judgment. Patients were excluded if they required renal dialysis, had a previous intracranial hemorrhage, had gastrointestinal bleeding within 6 months, had a known bleeding diathesis or coagulation disorder, or required treatment with anticoagulants. Do not take new medicines that contain aspirin. In patients treated with PCI, it also reduces the rate of stent thrombosis.
Premature discontinuation increases the risk of myocardial infarction, stent thrombosis, brilinta package insert death. This site complies with the HONcode standard for trustworthy health information: Lab Values – A thru Z. You are encouraged to report negative side effects of prescription brilinta package insert to the FDA.
Strong inducers substantially reduce ticagrelor exposure and so decrease the efficacy of ticagrelor As with other oral P2Y 12 inhibitors, co-administration of opioid agonists delay and reduce the absorption of ticagrelor. Administer 90 mg twice daily during the first year after an ACS brilinta package insert.